May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Intravitreal triamcinolone for the treatment of macular edema from central retinal vein occlusion
Author Affiliations & Notes
  • J.E. Lee
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • E.C. Mavrofrides
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • W.E. Smiddy
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • I.U. Scott
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • P.J. Rosenfeld
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • H.W. Flynn Jr
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • T.G. Murray
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • A.M. Berrocal
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • C.A. Puliafito
    Department Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • Footnotes
    Commercial Relationships  J.E. Lee, None; E.C. Mavrofrides, None; W.E. Smiddy, None; I.U. Scott, None; P.J. Rosenfeld, None; H.W. Flynn Jr., None; T.G. Murray, None; A.M. Berrocal, None; C.A. Puliafito, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5238. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.E. Lee, E.C. Mavrofrides, W.E. Smiddy, I.U. Scott, P.J. Rosenfeld, H.W. Flynn Jr, T.G. Murray, A.M. Berrocal, C.A. Puliafito; Intravitreal triamcinolone for the treatment of macular edema from central retinal vein occlusion . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5238.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Objective: To investigate the safety and efficacy of intravitreal triamcinolone for the treatment of vision loss secondary to macular edema from central retinal vein occlusion (CRVO). Methods: Retrospective consecutive case series. The current study included all patients at the Bascom Palmer Eye Institute treated with intravitreal injections of triamcinolone acetonide (4 mg) for the treatment of macular edema from CRVO between June 1, 2001 and June 1, 2003. Results: Forty–one eyes of 41 patients were reviewed. The median age was 78 years old (range, 42–98) with a median follow–up of 6.5 months (2–19). The duration of macular edema was between 1 to 20 months. Median visual acuity was 20/400 (20/60–CF) at baseline. Following treatment, median visual acuity was 20/300 (20/40–CF) at 1 month, 20/300 (20/30–CF) at 3 months, and 20/400 (20/30–LP) at 6 months. The median change in ETDRS equivalent lines was +1 line at 1 month, +2 lines at 3 months, and +2 lines at 6 months. Visual acuity was improved by at least 3 ETDRS equivalent lines in 12/33 eyes (36%) at 1 month, 9/27 (31%) at 3 months, and 11/23 (48%) at 6 months. Median foveal thickness as measured by optical coherence tomography (OCT) was 539 µm (192–768) at baseline, compared to 252 µm (202–632) at 1 month, 313 µm (191–540) at 3 months, and 234 µm (194–602) at 6 months. Additional injections were performed in 2/41 eyes (5%) at 1 month, 7/40 (18%) at 3 months, and 14/27 (52%) at 6 months. Intraocular pressure increased more than 10 mmHg compared to baseline in 5/33 eyes (15%) at 1 month, 4/27 (15%) at 3 months, and 2/23 (9%) at 6 months. There were no cases of endophthalmitis. Rubeosis developed in 8 eyes (20%), and glaucoma filtering surgery was performed in 1 eye (3%). Two patients (5%) experienced significant progression of cataract requiring extraction. Conclusions: In the current study, a 3–line visual acuity improvement occurred in 48% of patients at the 6 month examination, but the median visual acuity was unchanged. Recurrent macular edema and the need for retreatment were common.

Keywords: retina • drug toxicity/drug effects • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×